These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 11640994)

  • 1. Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study.
    Tamás G; Marre M; Astorga R; Dedov I; Jacobsen J; Lindholm A;
    Diabetes Res Clin Pract; 2001 Nov; 54(2):105-14. PubMed ID: 11640994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial.
    Home PD; Lindholm A; Riis A;
    Diabet Med; 2000 Nov; 17(11):762-70. PubMed ID: 11131100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial.
    Mathieu C; Bode BW; Franek E; Philis-Tsimikas A; Rose L; Graungaard T; Birk Østerskov A; Russell-Jones D
    Diabetes Obes Metab; 2018 May; 20(5):1148-1155. PubMed ID: 29316130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin.
    Rosenfalck AM; Thorsby P; Kjems L; Birkeland K; Dejgaard A; Hanssen KF; Madsbad S
    Acta Diabetol; 2000 Mar; 37(1):41-6. PubMed ID: 10928235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST
    Hirsch IB; Franek E; Mersebach H; Bardtrum L; Hermansen K
    Diabet Med; 2017 Feb; 34(2):167-173. PubMed ID: 26773446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the safety and effectiveness of insulin aspart with other bolus insulins in women with pre-existing Type 1 diabetes during pregnancy: A post hoc analysis of a prospective cohort study.
    Mathiesen ER; Alibegovic AC; Anil G; Dunne F; Halasa T; Ivanišević M; McCance DR; Nordsborg RB; Damm P;
    Diabet Med; 2024 Oct; 41(10):e15411. PubMed ID: 39115159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women.
    Mathiesen ER; Kinsley B; Amiel SA; Heller S; McCance D; Duran S; Bellaire S; Raben A;
    Diabetes Care; 2007 Apr; 30(4):771-6. PubMed ID: 17392539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes.
    Raskin P; Guthrie RA; Leiter L; Riis A; Jovanovic L
    Diabetes Care; 2000 May; 23(5):583-8. PubMed ID: 10834413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial.
    Buse JB; Carlson AL; Komatsu M; Mosenzon O; Rose L; Liang B; Buchholtz K; Horio H; Kadowaki T
    Diabetes Obes Metab; 2018 Dec; 20(12):2885-2893. PubMed ID: 30259644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1).
    Russell-Jones D; Bode BW; De Block C; Franek E; Heller SR; Mathieu C; Philis-Tsimikas A; Rose L; Woo VC; Østerskov AB; Graungaard T; Bergenstal RM
    Diabetes Care; 2017 Jul; 40(7):943-950. PubMed ID: 28356319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.
    Hermansen K; Fontaine P; Kukolja KK; Peterkova V; Leth G; Gall MA
    Diabetologia; 2004 Apr; 47(4):622-9. PubMed ID: 15298338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial.
    Bode BW; Iotova V; Kovarenko M; Laffel LM; Rao PV; Deenadayalan S; Ekelund M; Larsen SF; Danne T
    Diabetes Care; 2019 Jul; 42(7):1255-1262. PubMed ID: 31076415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial.
    Bowering K; Case C; Harvey J; Reeves M; Sampson M; Strzinek R; Bretler DM; Bang RB; Bode BW
    Diabetes Care; 2017 Jul; 40(7):951-957. PubMed ID: 28483786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple mealtime administration of biphasic insulin aspart 30 versus traditional basal-bolus human insulin treatment in patients with type 1 diabetes.
    Chen JW; Lauritzen T; Bojesen A; Christiansen JS
    Diabetes Obes Metab; 2006 Nov; 8(6):682-9. PubMed ID: 17026493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes.
    Christiansen JS; Vaz JA; Metelko Z; Bogoev M; Dedov I
    Diabetes Obes Metab; 2003 Nov; 5(6):446-54. PubMed ID: 14617231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes.
    Ligthelm RJ; Mouritzen U; Lynggaard H; Landin-Olsson M; Fox C; le Devehat C; Romero E; Liebl A
    Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):511-9. PubMed ID: 17115349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of insulin aspart with basal insulin is associated with improved glycemic control in Indian patients with uncontrolled type 2 diabetes mellitus: the A1chieve observational study.
    Banerjee S; Maji D; Baruah M
    J Assoc Physicians India; 2013 Jan; 61(1 Suppl):24-7. PubMed ID: 24482984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter, open-label, nonrandomized, observational safety study in subjects using insulin aspart in basal-bolus regimen for the treatment of diabetes.
    Krzymień J; Kobli T; Nazar M
    Pol Arch Med Wewn; 2010 Nov; 120(11):444-50. PubMed ID: 21102380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.